PE: How do global pharma growth strategies differ from domestic strategies? Ackerman: There are two different models for ...

Q3 2025 Management View Peter Beetham, Co-Founder, Interim CEO, President, and COO, emphasized the company's "significant ...

Q3 2025 Management View Matthew Duffy, Chief Business Officer & Co-CEO of Hope Therapeutics, opened the call stating, "Since the beginning of the third quarter, NRx has made transformative progress in ...

EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) ("EnviroGold" or the "Company") is pleased to announce the publication of ...

AIRJ Expands Strategic Partnerships and Advances Productization of AirJoule™ Systems Ahead of Commercial Deployments in 2026 ...

The collaboration marks a key milestone under the Smart and Autonomous Vehicle Industries (SAVI) cluster, accelerating ...

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio ...

The FDA has granted full approval to Kura Oncology and Kyowa Kirin’s Komzifti (ziftomenib), marking the first FDA-approved once-daily, oral menin inhibitor for adults with relapsed or refractory (R/R) ...

The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med ...

HIGHLIGHTS Conference Call Information The Company will hold a conference call to discuss its financial results for the second quarter of 2025 at 8:30 a.m. ET on Friday, November 14, 2025.

Boron’s inclusion on the 2025 U.S. Critical Minerals List reinforces 5E’s role as America’s next advanced-stage, domestic ...

She reported plans to expand the commercial portfolio with the DARE to RESTORE vaginal probiotic line, targeting a U.S. launch in the first quarter of 2026, and DARE to RECLAIM, a combination ...